References

Authoritative and comprehensive sources we used to make this site

Our goal is to synthesize the high quality information and recommendations provided by other organizations into something that is easy to use in practice. These are the sources that we depend on for the information found on this site.

Guidelines

 
  • Incidentaloma

    • European: Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467. PMID: 27390021.

    • Candian (endorsed by the American Urological Association): Rowe NE, Kumar RM, Schieda N, et al. Canadian Urological Association guideline: Diagnosis, management, and followup of the incidentally discovered adrenal mass. Can Urol Assoc J. 2023;17(2):12-24. doi:10.5489/cuaj.8248

    • Korean: Lee JM, Kim MK, Ko SH, et al. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017;32(2):200-218. doi:10.3803/EnM.2017.32.2.200

    • American (endocrine surgeons): Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary. JAMA Surgery. 2022;157(10):870-877. doi:10.1001/jamasurg.2022.3544

    • American (American College of Radiology white paper): Mayo-Smith WW, Song JH, Boland GL, et al. Management of incidental adrenal masses: a white paper of the acr incidental findings committee. Journal of the American College of Radiology. 2017;14(8):1038-1044.

  • Conn’s syndrome: 

    • John W. Funder, Robert M. Carey, Franco Mantero, M. Hassan Murad, Martin Reincke, Hirotaka Shibata, Michael Stowasser, William F. Young, Jr, The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 101, Issue 5, 1 May 2016, Pages 1889–1916, https://doi.org/10.1210/jc.2015-4061 (from NCCN)

  • Cushing’s syndrome: 

    • Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29. PMID: 26222757; PMCID: PMC4525003.(from NCCN)

  • Pheochromocytoma: 

    • Jacques W. M. Lenders, Quan-Yang Duh, Graeme Eisenhofer, Anne-Paule Gimenez-Roqueplo, Stefan K. G. Grebe, Mohammad Hassan Murad, Mitsuhide Naruse, Karel Pacak, William F. Young, Jr, Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 99, Issue 6, 1 June 2014, Pages 1915–1942, https://doi.org/10.1210/jc.2014-1498 (from NCCN)

    • European Network for the Study of Adrenal Tumors http://www.ensat.org/page-1652177

  • Adrenocortical carcinoma

  • Imaging

    • American College of Radiology Appropriateness Criteria: Adrenal Mass Evaluation https://acsearch.acr.org/docs/69366/Narrative/?_ga=2.186016288.840016715.1634540127-2043902518.1634105739

    • Mayo-Smith WW, Song JH, Boland GL, et al. Management of incidental adrenal masses: a white paper of the acr incidental findings committee. Journal of the American College of Radiology. 2017;14(8):1038-1044. https://www.jacr.org/article/S1546-1440(17)30551-3/fulltext

NCCN Guidelines

 

Sections of the National Comprehensive Cancer Network (NCCN) Neuroendocrine and Adrenal Tumor Guidelines (v2.2021) considered for this site include:

  • AGT 1-5

  • PHEO 1-3

  • NE C

  • MS 3

  • MS 26-30

  • MS 30-34